
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
                                    Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa | 
|---|---|---|---|---|---|---|
- 首创的直接作用于Nectin-4(尿路上皮肿瘤中高表达的一种蛋白)的一种抗体-药物偶联药物1,2 - -...
批准基于对转移性去势抵抗性前列腺癌亚洲患者的Asian PREVAIL研究 东京,2019年11月26日-...
- 研究达到安全性结局,并且71%局部晚期或转移性尿路上皮(膀胱)癌患者有确定缓解 – -...
Read more about Seattle Genetics和安斯泰来宣布试验用药物Enfortumab Vedotin与免疫疗法Pembrolizumab联用作为晚期膀胱癌一线治疗的1期试验结果
东京与旧金山,2019年9月20日——安斯泰来制药公司(TSE:4503,总裁兼CEO:Kenji Yasukawa,Ph.D.,“安斯泰来”)与FibroGen, Inc. (Nasdaq:FGEN, Interim...
-FDA审评截止日期为2020年3月15日- 华盛顿波赛尔与东京,2019年9月16日——Seattle Genetics, Inc....
Read more about 美国食品与药品管理局批准对Enfortumab Vedotin治疗局部晚期或转移性尿路上皮癌的生物制剂许可申请进行优先审评
